Synthesis and LC-MS/MS analysis of desmosine-CH2, a potential internal standard for the degraded elastin biomarker desmosine. 2014

Yuko Murakami, and Rina Suzuki, and Hiroto Yanuma, and Jiangtao He, and Shuren Ma, and Gerard M Turino, and Yong Y Lin, and Toyonobu Usuki
Department of Materials and Life Sciences, Faculty of Science and Technology, Sophia University, 7-1 Kioicho, Chiyoda-ku, Tokyo 102-8554, Japan. t-usuki@sophia.ac.jp.

Desmosine-CH2, an analog of the elastic tissue degradation biomarker desmosine, can be regarded as a potential internal standard for precise quantification of desmosines by LC-MS/MS. In this study, the chemical synthesis of desmosine-CH2 was completed in 22% overall yield in five steps. The LC-MS/MS analysis of desmosine-CH2 was also achieved.

UI MeSH Term Description Entries
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D002853 Chromatography, Liquid Chromatographic techniques in which the mobile phase is a liquid. Liquid Chromatography
D003895 Desmosine A rare amino acid found in elastin, formed by condensation of four molecules of lysine into a pyridinium ring. 4-(4-Amino-4-Carboxybutyl)-1-(5-Amino-5-Carboxypentyl)-3,5-bis(3-Amino-3-Carboxypropyl)pyridinium
D004549 Elastin alpha-Elastin,kappa-Elastin,alpha Elastin,kappa Elastin
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D053719 Tandem Mass Spectrometry A mass spectrometry technique using two (MS/MS) or more mass analyzers. With two in tandem, the precursor ions are mass-selected by a first mass analyzer, and focused into a collision region where they are then fragmented into product ions which are then characterized by a second mass analyzer. A variety of techniques are used to separate the compounds, ionize them, and introduce them to the first mass analyzer. For example, for in GC-MS/MS, GAS CHROMATOGRAPHY-MASS SPECTROMETRY is involved in separating relatively small compounds by GAS CHROMATOGRAPHY prior to injecting them into an ionization chamber for the mass selection. Mass Spectrometry-Mass Spectrometry,Mass Spectrometry Mass Spectrometry,Mass Spectrometry, Tandem

Related Publications

Yuko Murakami, and Rina Suzuki, and Hiroto Yanuma, and Jiangtao He, and Shuren Ma, and Gerard M Turino, and Yong Y Lin, and Toyonobu Usuki
September 2013, Analytical biochemistry,
Yuko Murakami, and Rina Suzuki, and Hiroto Yanuma, and Jiangtao He, and Shuren Ma, and Gerard M Turino, and Yong Y Lin, and Toyonobu Usuki
January 2015, Bioorganic & medicinal chemistry letters,
Yuko Murakami, and Rina Suzuki, and Hiroto Yanuma, and Jiangtao He, and Shuren Ma, and Gerard M Turino, and Yong Y Lin, and Toyonobu Usuki
December 2021, Bioorganic & medicinal chemistry,
Yuko Murakami, and Rina Suzuki, and Hiroto Yanuma, and Jiangtao He, and Shuren Ma, and Gerard M Turino, and Yong Y Lin, and Toyonobu Usuki
November 2022, RSC advances,
Yuko Murakami, and Rina Suzuki, and Hiroto Yanuma, and Jiangtao He, and Shuren Ma, and Gerard M Turino, and Yong Y Lin, and Toyonobu Usuki
March 2012, Chemical communications (Cambridge, England),
Yuko Murakami, and Rina Suzuki, and Hiroto Yanuma, and Jiangtao He, and Shuren Ma, and Gerard M Turino, and Yong Y Lin, and Toyonobu Usuki
July 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Yuko Murakami, and Rina Suzuki, and Hiroto Yanuma, and Jiangtao He, and Shuren Ma, and Gerard M Turino, and Yong Y Lin, and Toyonobu Usuki
December 2003, Biochimica et biophysica acta,
Yuko Murakami, and Rina Suzuki, and Hiroto Yanuma, and Jiangtao He, and Shuren Ma, and Gerard M Turino, and Yong Y Lin, and Toyonobu Usuki
February 2006, Analytical chemistry,
Yuko Murakami, and Rina Suzuki, and Hiroto Yanuma, and Jiangtao He, and Shuren Ma, and Gerard M Turino, and Yong Y Lin, and Toyonobu Usuki
April 2017, Analytical and bioanalytical chemistry,
Yuko Murakami, and Rina Suzuki, and Hiroto Yanuma, and Jiangtao He, and Shuren Ma, and Gerard M Turino, and Yong Y Lin, and Toyonobu Usuki
April 2021, Journal of mass spectrometry and advances in the clinical lab,
Copied contents to your clipboard!